Correlation Between Denali Therapeutics and Xeris Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Denali Therapeutics and Xeris Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Denali Therapeutics and Xeris Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Denali Therapeutics and Xeris Pharmaceuticals, you can compare the effects of market volatilities on Denali Therapeutics and Xeris Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Denali Therapeutics with a short position of Xeris Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Denali Therapeutics and Xeris Pharmaceuticals.

Diversification Opportunities for Denali Therapeutics and Xeris Pharmaceuticals

-0.47
  Correlation Coefficient

Very good diversification

The 3 months correlation between Denali and Xeris is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding Denali Therapeutics and Xeris Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xeris Pharmaceuticals and Denali Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Denali Therapeutics are associated (or correlated) with Xeris Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xeris Pharmaceuticals has no effect on the direction of Denali Therapeutics i.e., Denali Therapeutics and Xeris Pharmaceuticals go up and down completely randomly.

Pair Corralation between Denali Therapeutics and Xeris Pharmaceuticals

Given the investment horizon of 90 days Denali Therapeutics is expected to under-perform the Xeris Pharmaceuticals. In addition to that, Denali Therapeutics is 1.04 times more volatile than Xeris Pharmaceuticals. It trades about -0.42 of its total potential returns per unit of risk. Xeris Pharmaceuticals is currently generating about -0.03 per unit of volatility. If you would invest  361.00  in Xeris Pharmaceuticals on October 9, 2024 and sell it today you would lose (7.00) from holding Xeris Pharmaceuticals or give up 1.94% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Denali Therapeutics  vs.  Xeris Pharmaceuticals

 Performance 
       Timeline  
Denali Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Denali Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in February 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.
Xeris Pharmaceuticals 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Xeris Pharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Xeris Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Denali Therapeutics and Xeris Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Denali Therapeutics and Xeris Pharmaceuticals

The main advantage of trading using opposite Denali Therapeutics and Xeris Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Denali Therapeutics position performs unexpectedly, Xeris Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xeris Pharmaceuticals will offset losses from the drop in Xeris Pharmaceuticals' long position.
The idea behind Denali Therapeutics and Xeris Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Complementary Tools

Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.